日本のファーマコゲノミクス市場レポート：技術、用途、エンドユーザー、地域別、2025年～2033年

日本のファーマコゲノミクスの市場規模は2024年に3億7,840万米ドルに達しました。今後、IMARC Groupは、同市場が2033年までに6億7,110万米ドルに達し、2025～2033年の成長率（CAGR）は6.08％になると予測しています。医療インフラの発展、高齢化人口の増加、大手企業による継続的な研究開発活動、政府機関や医療機関による教育イニシアチブの高まりなどが市場を牽引する主な要因となっています。

本レポートで扱う主な質問

• 日本のファーマコゲノミクス市場はこれまでどのように推移し、今後どのように推移するのか？
• COVID-19が日本のファーマコゲノミクス市場に与えた影響は？
• 日本のファーマコゲノミクス市場の技術別区分は？
• 日本のファーマコゲノミクス市場の用途別区分は？
• 日本のファーマコゲノミクス市場のエンドユーザー別区分は？
• 日本のファーマコゲノミクス市場のバリューチェーンにおける様々なステージとは？
• 日本のファーマコゲノミクスの主な促進要因と課題は何か？
• 日本のファーマコゲノミクス市場の構造と主要プレーヤーは？
• 日本のファーマコゲノミクス市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
• 市場推定
• 調査手法

第3章 エグゼクティブサマリー

第4章 日本のファーマコゲノミクス市場：イントロダクション

• 概要
• 市場力学
• 業界動向
• 競合情報

第5章 日本のファーマコゲノミクス市場情勢

• 過去および現在の市場動向（2019～2024年）
• 市場予測（2025～2033年）

第6章 日本のファーマコゲノミクス市場：技術別内訳

• ポリメラーゼ連鎖反応
• マイクロアレイ
• DNAシーケンシング
• 質量分析
• 電気泳動
• その他

第7章 日本のファーマコゲノミクス市場：用途別内訳

• 腫瘍学
• 感染症
• 心血管疾患
• 神経疾患
• 精神医学
• 疼痛管理
• その他

第8章 日本のファーマコゲノミクス市場：エンドユーザー別内訳

• 病院と診療所
• 学術研究機関

第9章 日本のファーマコゲノミクス市場：競合情勢

• 概要
• 市場構造
• 市場企業のポジショニング
• 主要成功戦略
• 競合ダッシュボード
• 企業評価象限

第10章 主要企業のプロファイル

第11章 日本のファーマコゲノミクス市場：業界分析

• 促進要因、抑制要因、機会
• ポーターのファイブフォース分析
• バリューチェーン分析

第12章 付録

Japan pharmacogenomics market size reached USD 378.4 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 671.1 Million by 2033, exhibiting a growth rate (CAGR) of 6.08% during 2025-2033. The expanding healthcare infrastructure, increasing aging population, continual research, and development (R&D) activities by leading players, and rising educational initiatives by government bodies and healthcare organizations represent some of the key factors driving the market.

Pharmacogenomics is the study of how genes influence an individual's response to medications. This scientific discipline combines elements of pharmacology, which is the science of drugs, and genomics, which is the study of genes and their functions. The primary aim of pharmacogenomics is to optimize drug therapy, maximizing effectiveness while minimizing adverse effects. Pharmacogenomics allows for a more personalized approach to medicine. It allows for tailored medical therapy based on an individual's genetic makeup. This means that treatments can be specifically designed to work best for each person, enhancing effectiveness. Personalized treatment can reduce the financial burden on the healthcare system. Fewer trials and errors in prescribing medication mean that patients can potentially reach an effective treatment faster, reducing hospital stays and lowering overall healthcare costs. Pharmacogenomics can also benefit pharmaceutical companies by identifying new drug targets and assisting in the development of medication that is more effective and safer, which can lead to faster regulatory approval.

Japan Pharmacogenomics Market Trends:

The country's robust healthcare infrastructure, characterized by cutting-edge technology and advanced research facilities, is driving the market in Japan. Japan's reputation as a leader in the field of technology and medicine facilitates a supportive environment for the growth of pharmacogenomics, with significant investments in research and development. Moreover, the strong government support for genomics research is supporting the market. Regulatory policies and funding are geared towards encouraging innovations in personalized medicine, including pharmacogenomics. The Japanese government has launched several initiatives to accelerate research in genomics and its application in medical treatments, thereby creating a favorable ecosystem for the pharmacogenomics market to flourish. The aging population in Japan also plays a critical role in augmenting the market. Older individuals are more likely to have complex healthcare needs and multiple medications, making them ideal candidates for personalized treatment plans. Pharmacogenomics can offer optimized drug therapies that are both effective and safe for this demographic, reducing adverse drug reactions, which are a leading cause of hospitalization among the elderly. In addition, Japan has a relatively high incidence of certain diseases that can benefit from pharmacogenomic applications, including various types of cancer and cardiovascular disorders. The ability to tailor treatments for these prevalent conditions can improve outcomes and reduce healthcare costs, making pharmacogenomics an attractive option for both healthcare providers and patients. Furthermore, the market is fueled by increasing public awareness about the benefits of personalized medicine. Besides, educational initiatives by government bodies and healthcare organizations have also contributed to a greater understanding of the advantages of pharmacogenomics, thus encouraging more people to opt for such tests and treatments.

Japan Pharmacogenomics Market Segmentation:

Technology Insights:

• Polymerase Chain Reaction
• Microarray
• DNA Sequencing
• Mass Spectrometry
• Electrophoresis
• Others

Application Insights:

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Neurological Diseases
• Psychiatry
• Pain Management
• Others

End User Insights:

• Hospitals and Clinics
• Academic and Research Institutes

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

• How has the Japan pharmacogenomics market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan pharmacogenomics market?
• What is the breakup of the Japan pharmacogenomics market on the basis of technology?
• What is the breakup of the Japan pharmacogenomics market on the basis of application?
• What is the breakup of the Japan pharmacogenomics market on the basis of end user?
• What are the various stages in the value chain of the Japan pharmacogenomics market?
• What are the key driving factors and challenges in the Japan pharmacogenomics?
• What is the structure of the Japan pharmacogenomics market and who are the key players?
• What is the degree of competition in the Japan pharmacogenomics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Pharmacogenomics Market - Introduction

• 4.1 Overview
• 4.2 Market Dynamics
• 4.3 Industry Trends
• 4.4 Competitive Intelligence

5 Japan Pharmacogenomics Market Landscape

• 5.1 Historical and Current Market Trends (2019-2024)
• 5.2 Market Forecast (2025-2033)

6 Japan Pharmacogenomics Market - Breakup by Technology

• 6.1 Polymerase Chain Reaction
  • 6.1.1 Overview
  • 6.1.2 Historical and Current Market Trends (2019-2024)
  • 6.1.3 Market Forecast (2025-2033)
• 6.2 Microarray
  • 6.2.1 Overview
  • 6.2.2 Historical and Current Market Trends (2019-2024)
  • 6.2.3 Market Forecast (2025-2033)
• 6.3 DNA Sequencing
  • 6.3.1 Overview
  • 6.3.2 Historical and Current Market Trends (2019-2024)
  • 6.3.3 Market Forecast (2025-2033)
• 6.4 Mass Spectrometry
  • 6.4.1 Overview
  • 6.4.2 Historical and Current Market Trends (2019-2024)
  • 6.4.3 Market Forecast (2025-2033)
• 6.5 Electrophoresis
  • 6.5.1 Overview
  • 6.5.2 Historical and Current Market Trends (2019-2024)
  • 6.5.3 Market Forecast (2025-2033)
• 6.6 Others
  • 6.6.1 Historical and Current Market Trends (2019-2024)
  • 6.6.2 Market Forecast (2025-2033)

7 Japan Pharmacogenomics Market - Breakup by Application

• 7.1 Oncology
  • 7.1.1 Overview
  • 7.1.2 Historical and Current Market Trends (2019-2024)
  • 7.1.3 Market Forecast (2025-2033)
• 7.2 Infectious Diseases
  • 7.2.1 Overview
  • 7.2.2 Historical and Current Market Trends (2019-2024)
  • 7.2.3 Market Forecast (2025-2033)
• 7.3 Cardiovascular Diseases
  • 7.3.1 Overview
  • 7.3.2 Historical and Current Market Trends (2019-2024)
  • 7.3.3 Market Forecast (2025-2033)
• 7.4 Neurological Diseases
  • 7.4.1 Overview
  • 7.4.2 Historical and Current Market Trends (2019-2024)
  • 7.4.3 Market Forecast (2025-2033)
• 7.5 Psychiatry
  • 7.5.1 Overview
  • 7.5.2 Historical and Current Market Trends (2019-2024)
  • 7.5.3 Market Forecast (2025-2033)
• 7.6 Pain Management
  • 7.6.1 Overview
  • 7.6.2 Historical and Current Market Trends (2019-2024)
  • 7.6.3 Market Forecast (2025-2033)
• 7.7 Others
  • 7.7.1 Historical and Current Market Trends (2019-2024)
  • 7.7.2 Market Forecast (2025-2033)

8 Japan Pharmacogenomics Market - Breakup by End User

• 8.1 Hospitals and Clinics
  • 8.1.1 Overview
  • 8.1.2 Historical and Current Market Trends (2019-2024)
  • 8.1.3 Market Forecast (2025-2033)
• 8.2 Academic and Research Institutes
  • 8.2.1 Overview
  • 8.2.2 Historical and Current Market Trends (2019-2024)
  • 8.2.3 Market Forecast (2025-2033)

9 Japan Pharmacogenomics Market - Competitive Landscape

• 9.1 Overview
• 9.2 Market Structure
• 9.3 Market Player Positioning
• 9.4 Top Winning Strategies
• 9.5 Competitive Dashboard
• 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

• 10.1 Company A
  • 10.1.1 Business Overview
  • 10.1.2 Product Portfolio
  • 10.1.3 Business Strategies
  • 10.1.4 SWOT Analysis
  • 10.1.5 Major News and Events
• 10.2 Company B
  • 10.2.1 Business Overview
  • 10.2.2 Product Portfolio
  • 10.2.3 Business Strategies
  • 10.2.4 SWOT Analysis
  • 10.2.5 Major News and Events
• 10.3 Company C
  • 10.3.1 Business Overview
  • 10.3.2 Product Portfolio
  • 10.3.3 Business Strategies
  • 10.3.4 SWOT Analysis
  • 10.3.5 Major News and Events
• 10.4 Company D
  • 10.4.1 Business Overview
  • 10.4.2 Product Portfolio
  • 10.4.3 Business Strategies
  • 10.4.4 SWOT Analysis
  • 10.4.5 Major News and Events
• 10.5 Company E
  • 10.5.1 Business Overview
  • 10.5.2 Product Portfolio
  • 10.5.3 Business Strategies
  • 10.5.4 SWOT Analysis
  • 10.5.5 Major News and Events

11 Japan Pharmacogenomics Market - Industry Analysis

• 11.1 Drivers, Restraints and Opportunities
  • 11.1.1 Overview
  • 11.1.2 Drivers
  • 11.1.3 Restraints
  • 11.1.4 Opportunities
• 11.2 Porters Five Forces Analysis
  • 11.2.1 Overview
  • 11.2.2 Bargaining Power of Buyers
  • 11.2.3 Bargaining Power of Suppliers
  • 11.2.4 Degree of Competition
  • 11.2.5 Threat of New Entrants
  • 11.2.6 Threat of Substitutes
• 11.3 Value Chain Analysis

12 Appendix